Black Diamond Therapeutics Inc (BDTX)

[dcaf7]

St. Joseph's Hospital and Medical Center in Phoenix is initiating a Phase 0 "Study of BDTX-1535 in Recurrent High-Grade Glioma (HGG) Participants With EGFR Alterations or Fusions". The idea is to give patients BDTX-1535 prior to a planned resection. "During surgery, blood, tumor, and CSF samples will be collected to measure the amount of drug that is present in the samples. Participants with tumors demonstrating PK response will continue with once-daily BDTX-1535 treatment, continuously in 28-day cycles after surgery". Interesting. I guess it is the best way to study PK of drug in brain tumor.
https://classic.clinicaltrials.gov/ct2/show/NCT06072586?term=BDTX&draw=2&rank=3